News
CAPR
15.95
+2.57%
0.40
Noteworthy Thursday Option Activity: CAPR, KR, UPS
NASDAQ · 3d ago
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
NASDAQ · 4d ago
Weekly Report: what happened at CAPR last week (0203-0207)?
Weekly Report · 6d ago
Notable Wednesday Option Activity: MCK, CAPR, TDOC
NASDAQ · 02/05 20:24
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
NASDAQ · 02/05 11:38
Weekly Report: what happened at CAPR last week (0127-0131)?
Weekly Report · 02/03 12:08
Weekly Report: what happened at CAPR last week (0120-0124)?
Weekly Report · 01/27 12:13
Noteworthy Tuesday Option Activity: CAPR, WWD, MCD
NASDAQ · 01/21 20:26
Weekly Report: what happened at CAPR last week (0113-0117)?
Weekly Report · 01/20 12:01
Weekly Report: what happened at CAPR last week (0106-0110)?
Weekly Report · 01/13 12:02
Weekly Report: what happened at CAPR last week (1230-0103)?
Weekly Report · 01/06 12:13
Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating
TipRanks · 01/03 20:05
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
NASDAQ · 01/03 15:23
Capricor Therapeutics Stock Surges On BLA Submission for Cell Therapy To Treat Muscular Dystrophy: Retail’s Excited
Barchart · 01/03 02:56
Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock
Benzinga · 01/02 19:00
Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co.
Dow Jones · 01/02 16:27
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target
Benzinga · 01/02 16:18
Capricor Therapeutics: Strategic Advances and Regulatory Progress Drive Buy Rating
TipRanks · 01/02 15:45
Capricor completes BLA on time, requests priority review, says H.C. Wainwright
TipRanks · 01/02 15:35
Capricor completes U.S. marketing submission for lead candidate
Seeking Alpha · 01/02 14:57
More
Webull provides a variety of real-time CAPR stock news. You can receive the latest news about Capricor Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.